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MANYexperimental studies have been carried out using
snake venoms for the treatment  of animal tumors,
with controversial results. While some authors have
reported an antitumor effect of treatment with specific
snake  venom  fractions,  others  have  reported  no
effects after this treatment. The aim of this study was to
evaluate the effect of Bothrops jararaca venom (BjV)
on Ehrlich ascites tumor (EAT) cells in vivo and in
vitro. In the in vivo study, Swiss mice were inoculated
with EAT cells by the intraperitoneal (i.p.) route and
treated with BjV venom (0.4mg/kg, i.p.), on the 1st,
4th, 7th, 10th, and 13th days. Mice were evaluated for
total and differential cells number on the 2nd, 5th, 8th,
11th  and  14th  days.  The  survival  time  was  also
evaluated after 60 days of tumor growth. In the in vitro
study, EAT and normal peritoneal cells were cultivated
in the presence of different BjV concentrations (2.5,
5.0,  10.0,  20.0,  40.0,  and  80 mg)  and  viability  was
verified after 3, 6, 12 and 24h of cultivation. Results
were analyzed statistically by the Kruskal–Wallis and
Tukey  tests  at  the  5%  level  of  significance.  It  was
observed  that  in  vivo  treatment  with  BjV  induced
tumor growth inhibition, increased animal survival
time,  decreased  mortality,  increased  the  influx  of
polymorphonuclear leukocytes on the early stages of
tumor growth, and did not  affect the mononuclear
cells number. In vitro treatment with BjV produced a
dose-dependent toxic  effect on  EAT  and  peritoneal
cells,  with  higher  effects  against  peritoneal  cells.
Taken together, our results demonstrate that BjV has
an important antitumor effect. This is the first report
showing this in vivo effect for this venom.
Key  words:  Antitumor  effect,  Ehrlich  ascites  tumor,
Bothrops jararaca, Venom
Introduction
Many  experimental  studies  have  been  carried  out
using  snake  venoms  for  the  treatment  of  animal
tumors. However, we have seen many controversies
on  this  subject.  Some  authors  have  reported  that
tumor treatment with specific snake venom fractions
has an important toxic effect on tumor cells, while
others  have  reported  no  antitumor  effects  after
inoculation with snake venoms.1
The exact mechanisms that cause tumor regression
in experimental animals after treatment with crude
snake venom and/or any fraction of this venom still
are unknown.1According to Lipps,2 certain fractions
isolated from snake venoms revealed a direct cytolytic
activity  on  tumor  cells.  Markland,3 on  conducting
research on crotalase, proposed that malignant cells
would  produce  a  microenvironment  around  them,
using substances of the host itself that protected them
against defensive responses of the immune  system.
This microenvironment would be composed of fibrin
deposits  from  the  nearby  blood  vessels.  Crotalase
apparently destroyed the microenviroment produced
by the tumor cells attacking fibrinogen directly, which
led to the formation of soluble fibrin monomers, or
abnormal  fibrin  microclots,  that  were  rapidly
removed by secondary activation of the fibrinolytic
system. Thus, immunological masking would not have
occurred,  which  would  leave  tumor  cells  unpro-
tected. The  literature  demonstrates also  that  snake
venoms  may  induce  apoptosis in  both  normal  and
tumor cells.4–12 In most of these works, the proposed
apoptosis induction mechanism was H2O2production
induced by the venom enzyme L-amino acid oxidase.
This enzyme was purified from Crotalus adamanteus
venom  and  its  structure  showed  a  high  degree  of
homology with murine interleukin-4.13
However, it has been demonstrated that continuous
contact of venom and tumor cells was necessary to
obtain  an  antitumor  effect. Yoshikura  et  al.14 eval-
uated the effects of Trimeresurus flavoviridis crude
venom and the hemorrhagic principles  in  different
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caused morphological and physiological alterations in
tumor cells without causing cellular death. However,
when  these  altered  cells  were  removed  from  the
venom-containing  medium  and  placed  in  a  venom-
free culture medium, they showed normal morphol-
ogy and physiology and grew in the medium. Leung et
al.15 corroborated this and reported that the cardio-
toxin from Naja sp. venom shows a cytolytic effect
on  Ehrlich  ascites  tumors  cells  and  that  cytolysis
progression  required  continuous  venom  presence.
This cytolytic activity completely stopped if the toxin
was removed from the medium.
It can be considered that antitumor effects of snake
venoms depend on the venom biodistribution time.
Tanigawa et al.16 demonstrated that jararafibrase-I and
jararafibrase-II, two fibrinolytic/hemorrhagic enzymes
of  Bothrops  jararaca venom  (BjV),  show  rapid
biodistribution in the body. Five minutes after intra-
venous inoculation in mice, its concentration in blood
decreases by  60%.  Similarly, Thwin et al.17 showed
that Vipera russeli venom inoculated intravenously in
mice was rapidly eliminated in urine.
The literature shows that mononuclear (MN) leu-
kocytes  may  effectively  participate  in  tumor  cell
elimination.18–26 A  previous  study27 evaluated  the
percentage of macrophage spreading and found that,
after  treatment  with  Crotalus  durissus  terrificus
venom, they were quite spread out with increases in
size  and  presence  of  large  cytoplasmatic  vacuoles,
suggesting  high  cellular  activity. This  increase  was
not observed in non-venom groups. However, Rabi-
novitch  and  Destefano28 demonstrated that proteo-
lytic enzymes may induce macrophage spreading as
they are capable of removing macromolecular com-
ponents from  the  cell  surface and affecting  macro-
phage surface receptors, resulting in a higher affinity
of the cell membrane to the substrate. This suggests
that although an increase in macrophage spreading
percentage has been observed,27 this may  not lead
to  an  increase  in  the  functional  activity  of  these
cells.
Most  studies  report  on  different  snake  venoms,
mainly Crotalus spp. and Naja spp.1There was only
one  study  with  BjV,  which  reports  a  cytophatic
effect on normal and tumor cells in vitro.29 The in
vivo antitumor effect of this venom was not studied.
The objective of the present paper is to evaluate the




Swiss  strain  male  mice,  4–6  weeks  old,  from  our
own  animal  facilities  were  used  throughout  the
experiment.
Venoms
BjV was obtained from snakes maintained in captivity
at The Center for the Study of Venoms and Venomous
Animals of S˜ ao Paulo State University, Brazil. Newly
extracted  venom  was  centrifuged  for  10min  at
1500rpm, filtered using a GSWP00250 Millipore filter
and then lyophilized. The lethal dose 50 (LD50) for
this  venom  has  been  previously  determined  as
2.4mg/kg of animal weight. The venom was stored at
4°C  during  the  experiment.  Preliminary  protocols
shown  that  0.4mg/kg  BjV  was  efficient  for  tumor
growth inhibition.
Ehrlich ascites tumor
The tumor was maintained in Swiss mice in the ascitic
form. Tumor cells were collected by aspiration with a
Pasteur pipette, centrifuged for 10min at 200 ´ g, and
washed twice with phosphate-buffered saline (PBS)
(pH 7.2). Cell viability was evaluated by the trypan
blue  exclusion  test,  and  only  cell  suspensions  that
presented more than 95% viability were used.
Peritoneal cells
Cells  were  harvested  by  peritoneal  washing  using
3ml of sterile PBS. The number  of  cells  was deter-
mined  using  a  hemacytometer.  Differential  counts
were performed on fixed and stained cell suspensions
(0.5% crystal violet dissolved in 30% acetic acid).
In vivo experiment
Mice  were  inoculated  by  the  intraperitoneal  route
(i.p.) with 1 ´ 103 Ehrlich ascites tumor (EAT) cells
and  treated with BjV  (0.4mg/kg)  or  saline  (0.1ml,
i.p.). The first BjV dose was administered 24h after
tumor implantation and repeated five times in each
72-h  interval.  Additional  control  groups  with  no
tumor bearing were treated with BjV or saline, in the
same protocol of experimental groups. After 2, 5, 8,
11, and 14 days of EAT implantation, 10 animals from
each group were sacrificed in a sulfur ether chamber,
and peritoneal cells were analyzed for  tumor, poly-
morphonuclear  (PMN),  and  MN  cell  numbers. The
remaining 10 animals from each group were kept in
the laboratory for 60 days for survival analysis. These
procedures  were  repeated  twice  and  data  were
grouped for statistical analysis.
In vitro experiment
EAT  and  peritoneal  cells  were  cultivated  with  0
(control),  2.5,  5,  10,  20,  40,  and  80mg  of  BjV.
Peritoneal  washing  was  performed  on  mice  inocu-
lated with  EAT  cells  and  on  normal  mice.  Cellular
suspensions adjusted to 1 ´ 103 EAT cells and 5 ´ 103
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supplemented with 5% fetal bovine serum for 24h at
37°C and 5% CO2atmosphere.  The cultures were then
washed  and  the  cells  placed  in  RPMI  medium
containing BjV at different doses. After 3, 6, 12, and
24h, cell viabilities were analyzed. These procedures
were  repeated  twice  and  data  were  grouped  for
statistical analysis.
Statistical analysis
Data were analyzed by the Kruskall–Wallis or analysis
of variance tests for independent sets, and by the  Tukey
or  Student–Newman–Keuls  tests  for  differences
between the groups. The significance level was 5%.
Results
In vivo experiment
Animals inoculated with EAT cells and treated with
saline (G3) presented exponential growth of tumor
cells after the 8th day, with a total number of 70 ´ 106
cells/ml at the 14th day. In the animals of the group
inoculated with EAT cells and treated with BjV (G4),
a significant reduction in tumor cells was observed on
the 11th and 14th days; the final number was 0.7 ´
106 cells/ml (Fig. 1).
PMN leukocytes influx in animals inoculated with
EAT (G3) showed significant influx of these cells on
the 8th, 11th, and 14th days. Animals inoculated with
EAT  cells  and  treated  with  BjV  (G4)  showed  a
significant increase throughout the study. PMN leuko-
cyte influx  was also observed in non-tumor-bearing
animals treated with BjV (G2),  the BjV  only  group
(Fig. 2).
In addition, animals inoculated with EAT cells and/
or BjV (G2, G3, and G4) showed a significant influx in
MN leukocytes throughout the study (Fig. 3).
Survival  analysis  revealed that the animals inocu-
lated  with  EAT  cells  and  treated  with  BjV  have
increased  survival  times  and  decreased  mortality,
compared with untreated animals (Fig. 4).
In vitro experiment
All tested venom concentrations showed a toxic effect
on tumor cells. We observed higher toxicity when the
higher doses of BjV were used, and vice versa. We have
also observed that, for concentrations of 2.5, 5, and
10mg, there was a mean increase in cell viability at 6h
in comparison with 3h. This increase was not seen
with concentrations of 20, 40, and 80mg (Fig. 5).
Similar  to  the  tumor  cells,  all  the  tested  venom
concentrations showed a toxic effect on mice perito-
neal  cells,  with  higher  toxicity  associated  with
treatment with higher doses of venom (Fig. 6).
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FIG. 1. Distribution of the median of the number of EAT cells
on the 2nd, 5th, 8th, 11th, and 14th days of tumor growth.
Each box represents 25–75% values, with the median as an
internal line; the error bar represents the percentiles 10 and
90, and the circle represents the outliers. Statistics: 11th and
14th days, G3 > G4; p < 0.05.
FIG. 2. Distribution of the median of the number of PMN cells
on the 2nd, 5th, 8th, 11th, and 14th days of tumor growth.
Each box represents 25–75% values, with the median as an
internal line; the error bar represents the percentiles 10 and
90, and the circle represents the outliers. Statistics: 2nd day,
G2 = G4 > G1 = G3; 5th day, G4 > G1 = G3; 8th, 11th, and 14th
days, (G2 = G3 = G4) > G1; p < 0.05.
FIG. 3. Distribution of the median of the number of MN cells
on the 2nd, 5th, 8th, 11th, and 14th days of tumor growth.
Each box represents 25–75% values, with the median as an
internal line; the error bar represents the percentiles 10 and
90, and the circle represents the outliers. Statistics: 11th and
14th days, (G2 = G3 = G4) > G1; p < 0.05.The  comparative  in  vitro evaluation  showed  a
peritoneal cell viability rate significantly higher than
tumor  cells  after  3h  culture  at  2.5,  5,  and  10mg
venom.  At  20mg,  although  the  tumor  cell  mean
viability rate was higher than peritoneal cells, it was
not  statistically  significant. At  concentrations of  40
and  80mg,  the  tumor  cells  showed  significantly
higher  viability  than  the  peritoneal  cells. After  6h
culture at 2.5 and 5mg, we observed no significant
difference between tumor and peritoneal cells. At 10,
20, 40, and 80mg, however, tumor cell viability was
significantly higher than peritoneal cells. At 12h, only
the 2.5mg concentration showed no significant differ-
ence. For all the other concentrations (5, 10, 20, 40,
and 80mg), tumor cell viability was higher than the
normal  cells. At  the  end  of  the  experiment  (24h),
viability of tumor cells was higher than normal cells at
all venom concentrations (Figs 5 and 6).
Discussion
This study evaluated the effect of BjV treatment on
the kinetics of tumor growth, inflammatory influx,
and animal survival in vivo, and on its toxic and/or
mitotic effect in vitro.
Analysis of total number of cells in the peritoneal
cavity shows that the number of cells in the group
that received tumor cells and venom treatment was
around 10% of that of the group with tumor cells only.
This suggests that although there was tumor growth
in  the  treated group,  this  was of  lower  magnitude
than in the non-treated group.
With regard to number of  tumor cells, treatment
with  BjV  promoted  99%  tumor  growth  inhibition.
These data show  that treatment of  EAT  mice  with
0.4mg/kg of BjV induces major tumor growth inhibi-
tion. These  results  are  in  agreement  with  previous
studies evaluating the effects of BjV on tumor cells29
and  others  showing  an  antineoplastic  effect  asso-
ciated with snake venom treatment.30–41
Tumor growth inhibition caused by BjV was accom-
panied by inflammatory influx alterations.  Treatment of
EAT animals with BjV induced a significant increase of
PMN leukocytes in the initial stages (2nd and 5th days)
in comparison with the non-treated EAT group. This
suggests that tumor growth inhibition may be related to
PMN leukocyte influx at the beginning of the experi-
ment – the beginning of tumor growth. At this stage, the
presence of PMN leukocytes, attracted to the tumor
growth  site  and  activated  by  the  venom  either  by
oxygen free radical generation42 or modulation of the
inflammatory response via tumor necrosis factor-a43,
might  play  a  role  in  modifying  the  environment
necessary for tumor development.
With regard to MN cells, we observed an increase
of tumor growth from day 11 in all groups inoculated
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FIG. 4. Survival percentage of animals inoculated with EAT
cells and treated with BjV or saline solution (* p < 0.05).
FIG. 5. Cellular viability of tumor cells after 3, 6, 12, and 24h
of  cultivation in  RPMI medium  at  37°C  and 5%  CO2,  and
incubation with 2.5, 5, 10, 20, 40, and 80mg of BjV. Each point
represents the mean and the standard error values (n = 48).
Statistics: 3h, (G1 = G2) > (G3 = G4 = G5 = G6); (G1 = G2 = G3)
> (G4 = G5) > G6; 12h, (G1 = G2) > G3 > G4 > G5 > G6; (G1 =
G2) > (G3 = G4 = G5) > G6; p < 0.05.
FIG. 6. Cellular viability of peritoneal cells after 3, 6, 12, and
24h of cultivation in RPMI medium at 37°C and 5% CO2, and
incubation with 2.5, 5, 10, 20, 40, and 80mg of BjV. Each point
represents the mean and the standard error values (n = 48).
Statistics: 3h, G1 > (G2 = G3) > (G4 = G5) > G6; 6h, (G1 = G2)
> G3 > G4 > G5 > G6; 12h, G1 > (G2 = G3 = G4) > G5 > G6;
24h, G1 > G2 > (G3 = G4) > (G5 = G6); p < 0.05.with EAT and/or venom. This indicates that both BjV
and the presence of EAT may induce an increase in
MN cell influx. Although no difference was detected
in the quantity of MN cells in the peritoneal cavity, we
do  not  rule  out  the  possibility  that  different  sub-
populations may be involved in tumor growth inhibi-
tion.18–26The inflammatory capacity of BjV has also
been demonstrated by the evaluation of PMN and MN
leukocyte influxes into the venom only group. This
group showed increased PMN on the 2nd, 8th, 11th
and 14th  days, and increased MN on the 11th  and
14th days.
Our study also evaluated the in vitro antimytotic
and/or  toxic  effect  of  BjV  on  EAT  cells  and  mice
peritoneal cells. We observed that the venom showed
a toxic effect both on tumor cells and peritoneal cells,
with  a  higher  toxicity  for  peritoneal  cells.  These
results are not in agreement with studies showing the
preferential effect of venom on tumor cells more than
normal cells,2,33 but are in agreement with work by
Rizzo and Tuchiya29 that showed the in vitro toxic
effect of BjV on HeLa, KB, and Hep-2 tumor cells, and
on normal rabbit kidney and chicken embryo cells.
These  authors29 have  also  demonstrated  that  the
tumor  cells  were  more  resistant  to  venom  than
normal cells, as seen in this study.
BjV  has  different  actions,  such  as  cytotoxic
action.44,45 It  is  possible,  then,  that  this  venom’s
proteolytic enzymes may be responsible for the death
of  tumor  and  peritoneal  cells,  as  suggested  by
Lipps.2
However, in the in vitro cultivation conditions used
in this study, the venom remained in direct contact
with cells for 24h. In the in vivo study, immediately
after venom inoculation, the biodistribution process
starts and it is soon eliminated from the peritoneal
cavity,  as  previous  demonstrated.16,17 Therefore,  in
contrast to the in vitro study, we can suggest that Bj
venom does not act for a long period of time on tumor
cells in vivo. Also, even in vitro at 10mg concentra-
tion, corresponding to 0.4mg/kg concentration in a
25g  animal,  tumor  cell  viability  after  24h  venom
contact was  56.1%. Assuming  that this  toxic  effect
was repeated in vivo, the non-affected part (43.9%)
could  still  continue  to  multiply,  leading  to  tumor
growth despite venom treatment. This can be seen in
the in vivo study since, for the venom-treated EAT
group, the reduction of tumor growth was not 100%.
Even  after  venom  treatment,  some  animals  still
showed  tumor  growth.  A  similar  observation  was
reported by Yoshikura et al.14 and Leung et al.15
Although the antineoplastic effect of venom treat-
ment  has  been  observed  in  vivo and  works  on
apoptosis  induction  have  been  performed  only  in
vitro,4–12 we  can  consider  that  the  apoptotic  pro-
cesses may be involved in the growth inhibition of the
EAT.  In  addition,  L-amino  acid  oxidase,  the  main
venom  enzyme  associated  with  apoptotic  proces-
ses,13 has  been  described  as  one  of  the  venom
components  from  all  snakes  of  the  Bothrops
genus,46,47 and  therefore  we  cannot  exclude  the
possible  action  of  this  enzyme  on  EAT  cells.  It  is
important to emphasize that, as already discussed for
the venom effect on tumor cells, venom biodistribu-
tion  in  the  body  should  also  be  considered  for
apoptosis; it would be important to demonstrate that
the venom has enough contact time with tumor cells
to induce apoptosis.
In the in vitro study, we also observed that tumor
cells were more resistant to the venom toxic effect
than peritoneal cells. We believe that in vitro induc-
tion of apoptosis may have a major role in  cellular
death.  As  we  observed  a  higher  sensitivity  from
peritoneal cells to venom, and as it is a characteristic
of this venom to induce apoptosis, we can suggest
that the peritoneal cells may be more susceptible to
the  apoptotic  effect  of  the  venom  than  the  tumor
cells.
Taken together, our results demonstrated that BjV
has  an  important  antitumor  effect. This  is  the  first
report  showing  this  in  vivo effect  for  this  venom.
Future  studies  with  protein  fractions  of  BjV  may
reveal  some  biological  product  will  contribute  to
improve the antitumor effect.
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